2seventy Bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

2seventy bio, Inc. announced that the Phase I trial of the PLAT-08 study of SC-DARIC33 in AML has been paused by Seattle Children’s, the Company’s partner and the regulatory sponsor of the study. The pause was instituted as part of the clinical study protocol stopping rules in response to a recent Grade 5 serious adverse event and was followed by the required notification to the US FDA.